Xenon Pharmaceuticals Inc. Common Shares XENE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T06:56:31.436Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:56:35.041143341Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T06:53:00.503782+00:00
Xenon Pharmaceuticals Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 35.51 | 70.4% | 11.5% | |||
| 25Δ | 36.30 | 69.9% | 10.0% | |||
| 30Δ | 43.49 | 90.3% | 13.8% | 37.10 | 69.4% | 8.5% |
| 35Δ | 42.96 | 99.0% | 13.3% | 37.86 | 72.5% | 7.6% |
| 40Δ | 38.59 | 79.4% | 7.1% | |||
| 45Δ | 39.32 | 86.2% | 6.6% | |||
| 50Δ | 39.66 | 61.7% | 5.1% | 40.05 | 92.6% | 6.1% |
| 55Δ | 39.02 | 65.1% | 4.6% | 40.95 | 91.9% | 5.3% |
| 60Δ | 38.38 | 68.5% | 4.1% | 41.84 | 91.2% | 4.4% |
| 65Δ | 37.73 | 71.9% | 3.6% | 42.94 | 93.5% | 3.6% |
| 70Δ | 44.65 | 104.4% | 3.2% | |||
| 75Δ | 45.85 | 102.8% | 2.5% | |||
| 80Δ | 46.92 | 97.9% | 1.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 35.51
- IV
- 70.4%
- B/E move
- 11.5%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 36.30
- IV
- 69.9%
- B/E move
- 10.0%
30Δ
- Pseudo strike
- 43.49
- IV
- 90.3%
- B/E move
- 13.8%
- Pseudo strike
- 37.10
- IV
- 69.4%
- B/E move
- 8.5%
35Δ
- Pseudo strike
- 42.96
- IV
- 99.0%
- B/E move
- 13.3%
- Pseudo strike
- 37.86
- IV
- 72.5%
- B/E move
- 7.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 38.59
- IV
- 79.4%
- B/E move
- 7.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 39.32
- IV
- 86.2%
- B/E move
- 6.6%
50Δ
- Pseudo strike
- 39.66
- IV
- 61.7%
- B/E move
- 5.1%
- Pseudo strike
- 40.05
- IV
- 92.6%
- B/E move
- 6.1%
55Δ
- Pseudo strike
- 39.02
- IV
- 65.1%
- B/E move
- 4.6%
- Pseudo strike
- 40.95
- IV
- 91.9%
- B/E move
- 5.3%
60Δ
- Pseudo strike
- 38.38
- IV
- 68.5%
- B/E move
- 4.1%
- Pseudo strike
- 41.84
- IV
- 91.2%
- B/E move
- 4.4%
65Δ
- Pseudo strike
- 37.73
- IV
- 71.9%
- B/E move
- 3.6%
- Pseudo strike
- 42.94
- IV
- 93.5%
- B/E move
- 3.6%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 44.65
- IV
- 104.4%
- B/E move
- 3.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 45.85
- IV
- 102.8%
- B/E move
- 2.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 46.92
- IV
- 97.9%
- B/E move
- 1.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 50.76% | |
| 50.40% | |
| 50.51% | |
| 51.84% | |
| 54.31% | |
| 55.67% | |
| 56.92% | |
| 53.43% | |
| 48.74% | |
| 57.76% |
Biotechnology
XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients…
More →ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is…
More →ZLAB
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is…
More →ZNTL
Description unavailable
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →